Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
SSP 47th Annual Meeting
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.23208 |
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.13553 |
| 10.18632/ONCOTARGET.14401 |
| 10.18632/ONCOTARGET.15422 |
| 10.18632/ONCOTARGET.16407 |
| 10.18632/ONCOTARGET.19087 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Top-10 Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here andhere.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
February 25, 2020
About The Cover
The cover for issue 8 of Oncotarget features Figure 8, "MLN4924 treatment induces DNA damage by stabilizing CDT1 and accumulates the cells in S phase which are enhanced by MLN4924/cisplatin co-treatment," byMisra, et al.
Table of Contents
Research Papers
| EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis |
https://doi.org/10.18632/oncotarget.27374 Raphaël Bergès,Aurélie Tchoghandjian,Arnauld Sergé,Stéphane Honoré,Dominique Figarella-Branger,Felix Bachmann,Heidi A. Lane, and Diane Braguer |
| 759-774 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
| Subcellular localization of FANCD2 is associated with survival in ovarian carcinoma |
https://doi.org/10.18632/oncotarget.27437 Sonali Joshi,Shawn Campbell,Jeong Y. Lim,Shannon McWeeney,Adam Krieg,Yukie Bean,Nadja Pejovic,Paulette Mhawech-Fauceglia, and Tanja Pejovic |
| 775-783 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
| Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment |
https://doi.org/10.18632/oncotarget.27485 Shrilekha Misra,Xiaoli Zhang,Nissar Ahmad Wani,Steven Sizemore, and Alo Ray |
| 784-800 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
| SLC25A32 sustains cancer cell proliferation by regulating flavin adenine nucleotide (FAD) metabolism |
https://doi.org/10.18632/oncotarget.27486 Valeria Santoro,Ilya Kovalenko,Kim Vriens,Stefan Christen,Andreas Bernthaler,Andrea Haegebarth,Sarah-Maria Fendt, and Sven Christian |
| 801-812 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release |
| Prolyl 4-hydroxylase alpha 1 protein expression risk-stratifies early stage colorectal cancer |
https://doi.org/10.18632/oncotarget.27491 Atsushi Tanaka,Yihua Zhou,Jinru Shia,Fiona Ginty,Makiko Ogawa,David S. Klimstra,Ronald C. Hendrickson,Julia Y. Wang, and Michael H. Roehrl |
| 813-824 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Press Release | Podcast | Video Interview |
Corrections
| Correction: High expression of CTHRC1 promotes EMT of epithelial ovarian cancer (EOC) and is associated with poor prognosis |
https://doi.org/10.18632/oncotarget.27370 Minzhi Hou,Zhiqiang Cheng,Hongwei Shen,Shanyang He,Yang Li,Yunping Pan,Chongjin Feng,Xinlin Chen,Yang Zhang,Millicent Lin,Liantang Wang, and Zunfu Ke |
| 825-826 |
| Correction | PDF | How to cite |
| Correction: Glioblastoma and glioblastoma stem cells are dependent on functional MTH1 |
https://doi.org/10.18632/oncotarget.27484 Linda Pudelko,Pegah Rouhi,Kumar Sanjiv,Helge Gad,Christina Kalderén,Andreas Höglund,Massimo Squatrito,Alberto J. Schuhmacher,Steven Edwards,Daniel Hägerstrand,Ulrika Warpman Berglund,Thomas Helleday, and Lars Bräutigam |
| 827-827 |
| Correction | PDF | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals